Kirn DH - Search Results

1

Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G. Geoerger B, et al. Among authors: kirn dh. Cancer Res. 2002 Feb 1;62(3):764-72. Cancer Res. 2002. PMID: 11830531

2

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.

Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH, Vassal G. Geoerger B, et al. Among authors: kirn dh. Br J Cancer. 2003 Aug 4;89(3):577-84. doi: 10.1038/sj.bjc.6601102. Br J Cancer. 2003. PMID: 12888833 Free PMC article.

3

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D. Nemunaitis J, et al. Cancer Res. 2000 Nov 15;60(22):6359-66. Cancer Res. 2000. PMID: 11103798 Clinical Trial.

4

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.

Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH. Rogulski KR, et al. Among authors: kirn dh. Cancer Res. 2000 Mar 1;60(5):1193-6. Cancer Res. 2000. PMID: 10728673

5

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.

Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Heise CC, et al. Among authors: kirn dh. Cancer Res. 1999 Jun 1;59(11):2623-8. Cancer Res. 1999. PMID: 10363984

6

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB. Ganly I, et al. Clin Cancer Res. 2000 Mar;6(3):798-806. Clin Cancer Res. 2000. PMID: 10741699 Clinical Trial.

7

Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.

Petit T, Davidson KK, Cerna C, Lawrence RA, Von Hoff DD, Heise C, Kirn D, Izbicka E. Petit T, et al. Anticancer Drugs. 2002 Jan;13(1):47-50. Anticancer Drugs. 2002. PMID: 11914640

8

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.

Heise CC, Williams A, Olesch J, Kirn DH. Heise CC, et al. Among authors: kirn dh. Cancer Gene Ther. 1999 Nov-Dec;6(6):499-504. doi: 10.1038/sj.cgt.7700071. Cancer Gene Ther. 1999. PMID: 10608346

9

Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.

Heise C, Lemmon M, Kirn D. Heise C, et al. Clin Cancer Res. 2000 Dec;6(12):4908-14. Clin Cancer Res. 2000. PMID: 11156251

10

Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.

Wein LM, Wu JT, Kirn DH. Wein LM, et al. Among authors: kirn dh. Cancer Res. 2003 Mar 15;63(6):1317-24. Cancer Res. 2003. PMID: 12649193

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters